ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Immune-Onc Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference

November 22, 2021 GMT

PALO ALTO, Calif.--(BUSINESS WIRE)--Nov 22, 2021--

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that management will participate in a fireside chat at the upcoming Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021, at 4:45pm Eastern Time.

Presentation Details
Evercore ISI 4th Annual HealthCONx Conference
Presentation Date: Tuesday, November 30, 2021
Presentation Time: 4:45 – 5:05 PM ET (Webinar)

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.

ADVERTISEMENT

Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The U.S. Food and Drug Administration granted IO-202 Orphan Drug Designation for treatment of AML in October 2020. The company also plans to evaluate IO-202 in solid tumors in 1H2022. IO-108, an antagonist antibody targeting LILRB2 (ILT4), entered clinic for solid tumors in October 2021. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies.

ADVERTISEMENT

The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays, and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211122006066/en/

CONTACT: MEDIA CONTACT

Tara Cooper

The Grace Communication Group

tara@gracegroup.us

media@immuneonc.com

650-303-7306

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Immune-Onc Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 11/22/2021 11:00 AM/DISC: 11/22/2021 11:02 AM

http://www.businesswire.com/news/home/20211122006066/en